Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Japan's Takeda says drug pipeline to lift sales to $48 billion in next decade

12/08/2020 | 09:46pm EDT
FILE PHOTO: A Takeda logo is seen in its research hub in Cambridge

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co said on Wednesday its drug pipeline is poised to drive annual sales up by more than 50%, to 5 trillion yen ($48.01 billion) in the next decade.

Japan's biggest drugmaker is trying to turn the spotlight on its growth prospects after its $59 billion takeover of Shire Plc, completed last year. Since the merger, the company's shares have underperformed domestic and global peers as it focused on selling $10 billion in non-core assets to reduce debt.

"One of the questions that we've had to ask ourselves is, how can we help our investor base better understand our pipeline, and assume the same energy and enthusiasm that we have?" research and development president Andy Plump said in an online briefing to analysts and media.

The company outlined a wave of 12 new drugs planned for the next few years, including a dengue fever vaccine and its Orexcin narcolepsy drugs, which it expects could deliver $6 billion in annual sales.

The 5 trillion yen sales target by March 2031 compares with estimated revenue of 3.2 trillion yen this fiscal year.

"Takeda's management is keenly aware of its poor stock performance and would like analysts to take a more bullish view of its pipeline," Jefferies analyst Stephen Barker wrote in a research note. "But analysts may not be convinced until more data is available."

The Shire acquisition, completed in January 2019, expanded Takeda's pipeline and diversified its global sales. But it also saddled the drugmaker with a large debt pile.

The company reached its goal of asset disposals when it agreed in August to sell its Japanese consumer healthcare business to Blackstone Group.

Takeda's shares, down 6.5% this year, rose 1.2% in Tokyo trading versus a 0.9% gain in the broader market.

(Reporting by Rocky Swift. Editing by Gerry Doyle)

By Rocky Swift


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BLACKSTONE INC. 0.82% 123.03 Delayed Quote.89.83%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.06% 3232 End-of-day quote.-13.93%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
10/13TR1 : Notification of Major Shareholding
DJ
10/13TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Expansion of Plasma Donation Cen..
BU
10/13Immusoft and Takeda Pharmaceutical Company Limited Collaborate to Discover and Develop ..
CI
10/12POSEIDA THERAPEUTICS : Takeda to Jointly Develop Novel Non-Viral In Vivo Gene Therapies
MT
10/12Poseida Therapeutics, Inc. Announces Research Collaboration with Takeda Pharmaceutical ..
CI
10/12Poseida Therapeutics, Takeda Pharmaceutical in Research, License Pact
DJ
10/08TAKEDA PHARMACEUTICAL : - FDA Advisory Committee Recommends Use of Investigational Drug Ma..
AQ
10/08TAKEDA PHARMACEUTICAL : Says FDA Panel Backs Use of Maribavir as Potential Treatment for C..
MT
10/08TAKEDA PHARMACEUTICAL : NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART,..
PU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 385 B 29 585 M 29 585 M
Net income 2022 252 B 2 200 M 2 200 M
Net Debt 2022 3 258 B 28 474 M 28 474 M
P/E ratio 2022 20,4x
Yield 2022 5,57%
Capitalization 5 082 B 44 517 M 44 425 M
EV / Sales 2022 2,46x
EV / Sales 2023 2,33x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 232,00 JPY
Average target price 4 551,43 JPY
Spread / Average Target 40,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.93%44 517
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657